BioNTech SE (BNTX) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BNTX Revenue Growth
Revenue Breakdown (FY 2025)
BNTX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
BNTX Revenue Analysis (2017–2025)
As of May 7, 2026, BioNTech SE (BNTX) generated trailing twelve-month (TTM) revenue of $2.86 billion, reflecting significant decline in growth of -24.5% year-over-year. The most recent quarter (Q4 2025) recorded $898.9 million in revenue, down 40.8% sequentially.
Looking at the longer-term picture, BNTX's 5-year compound annual growth rate (CAGR) stands at +41.7%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $18.98 billion in 2021.
Revenue diversification analysis shows BNTX's business is primarily driven by Other Sales (100%). With over half of revenue concentrated in Other Sales, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MRNA (-29.1% YoY), PFE (+1.4% YoY), and NVAX (-52.5% YoY), BNTX has underperformed the peer group in terms of revenue growth. Compare BNTX vs MRNA →
BNTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BNTXCurrent | $2.9B | -24.5% | +41.7% | -22.6% | |
 MRNA | $1.9B | -29.1% | +19.3% | -158.1% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% | |
 ARCT | $67M | -46.4% | +47.8% | -111.5% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% |
BNTX Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.76B | +0.2% | $2.14B | 77.6% | $-623,865,983 | -22.6% |
| 2024 | $2.75B | -28.0% | $2.21B | 80.3% | $-1,314,300,000 | -47.8% |
| 2023 | $3.82B | -77.9% | $3.22B | 84.3% | $690.4M | 18.1% |
| 2022 | $17.31B | -8.8% | $14.32B | 82.7% | $12.64B | 73.0% |
| 2021 | $18.98B | +3834.6% | $16.07B | 84.7% | $15.28B | 80.5% |
| 2020 | $482.3M | +344.1% | $423.0M | 87.7% | $-82,400,000 | -17.1% |
| 2019 | $108.6M | -14.9% | $91.2M | 84.0% | $-181,500,000 | -167.1% |
| 2018 | $127.6M | +107.1% | $113.9M | 89.3% | $-53,854,000 | -42.2% |
| 2017 | $61.6M | - | $52.3M | 84.9% | $-61,277,000 | -99.5% |
Full BNTX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BNTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BNTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BNTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBNTX — Frequently Asked Questions
Quick answers to the most common questions about buying BNTX stock.
Is BNTX's revenue growth accelerating or slowing?
BNTX revenue declined -24.5% year-over-year, contrasting with the 5-year CAGR of +41.7%. TTM revenue fell to $2.9B. This reverses the prior growth trend.
What is BNTX's long-term revenue growth rate?
BioNTech SE's 5-year revenue CAGR of +41.7% reflects the variable expansion pattern. Current YoY growth of -24.5% is below this long-term average.
How is BNTX's revenue distributed by segment?
BNTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.